A Phase 1/2 interventional study of PLX2853 and Carboplatin in Gynecologic Neoplasms and Epithelial Ovarian Cancer, sponsored by Opna Bio LLC. Terminated at 9 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-04.
Sponsored by Opna Bio LLC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States — 29 open to participants now, 50 under way, 8 of them phase 3. Carcinoma, Ovarian Epithelial · United States.
Among the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, this one is the 185th largest by enrollment of the 381 interventional ones that give a count, is one of 9 that started in 2020, is one of 51 in phase 1/2, and was the 437th registered.
798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.
Browse Carcinoma, Ovarian Epithelial studies →29 of the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States are open now. Recruiting first, the newest first:
Michael J. Goodheart · Sites in United States
Ages 18–99 · Women only
AstraZeneca · Sites in United States, Australia, Brazil and 10 more countries
Ages 18+ · Women only
AstraZeneca · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+ · Women only
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 18+ · Women only
Blue Earth Diagnostics · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 204 · Phase 2 230 · Phase 3 39 · Phase 4 1
First in 1991; this study’s year is marked. 9 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 45 across 585 interventional studies indexed under Carcinoma, Ovarian Epithelial.
Median enrollment 35 across the 381 interventional studies, 57 across the 34 observational. Of the 418 that completed or were terminated, 122 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 500 have an industry lead sponsor. The 10 most frequent:
Opna Bio LLC is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Opna Bio LLC has 1 study filed under Carcinoma, Ovarian Epithelial — fewer than ten, so there is no comparison to draw.
14 of the studies in Carcinoma, Ovarian Epithelial with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
| NCT06386887Case Comprehensive Cancer CenterFasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer | 2026-11 |
| NCT06395519858 Therapeutics, Inc.A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | 2026-12 |
| NCT05335993CanariaBio Inc.A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | 2026-12-30 |
| NCT05763199University of California, DavisStandardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer.
798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.
This study's enrollment of 37 is below the median of 45 across 585 interventional studies indexed under Carcinoma, Ovarian Epithelial.
Browse Carcinoma, Ovarian Epithelial studies →Opna Bio LLC is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Compared within Carcinoma, Ovarian Epithelial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genital Neoplasms, Female. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or cytologically confirmed diagnosis of 1 of the following, and must have per v1.1:
Platinum-resistant EOC (including fallopian tube or primary peritoneal cancer).
Exclusion Criteria:
Active known second with the exception of any of the following:
Receipt of anti-cancer therapy prior to Cycle 1 Day 1:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with ARID1A mutation-positive advanced gynecological malignancies
Drug: PLX2853
Subjects with platinum-resistant EOC
Drug: PLX2853 · Drug: Carboplatin
Subjects with platinum-resistant EOC
Drug: PLX2853 · Drug: Carboplatin
Subjects with platinum-resistant EOC
Drug: PLX2853 · Drug: Carboplatin
PLX2853 tablets
Carboplatin IV injection, 5 mg•min/mL
Phase 2a (PLX2853 Monotherapy): Number of Participants With Overall Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Overall response rate as measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Time frame: From 8 weeks of treatment for only PLX2853 (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months.
Phase 1b (PLX2853 + Carboplatin Combination): Establish the Number of Participants Reaching MTD/RP2D for the Combination of PLX2853 and Carboplatin
MTD is defined as the maximum tolerated dose, which is determined from dose-limiting toxicity. If DLTs are observed in 2 or more of 6 subjects (or ≥33% of the cohort) at a dose level, the dose at which this occurs will be considered intolerable and the MTD will have been exceeded. The MTD is the dose below the intolerable dose. RP2D is the recommended Phase 2 dose, which was determined to be 80 mg
Time frame: From time of first dose of PLX2853 and carboplatin until 30 days of end of treatment an average of 6 months.
Phase 2a (PLX2853 + Carboplatin Combination): Number of Participants Reaching ORR as Measured by RECIST v1.1
Overall response rate as measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Time frame: From 8 weeks of treatment with PLX2853 and Carboplatin (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months.
| Milestone | Phase 2a | Phase 1b Combination | Phase 1b | Phase 2a Combination |
|---|---|---|---|---|
| Started | 14 | 3 | 7 | 13 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 14 | 3 | 7 | 13 |
| Withdrew: Death | 4 | 3 | 3 | 4 |
| Withdrew: Study discontinued early | 10 | 0 | 4 | 8 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
Overall response rate as measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
No measurements were reported for this outcome.
MTD is defined as the maximum tolerated dose, which is determined from dose-limiting toxicity. If DLTs are observed in 2 or more of 6 subjects (or ≥33% of the cohort) at a dose level, the dose at which this occurs will be considered intolerable and the MTD will have been exceeded. The MTD is the dose below the intolerable dose. RP2D is the recommended Phase 2 dose, which was determined to be 80 mg
| Participants | PLX2853 Phase 2a Monotherapy | PLX2853 + Carboplatin Phase 1b/2a Combination Therapy |
|---|---|---|
| Phase 1b (PLX2853 + Carboplatin Combination): Establish the Number of Participants Reaching MTD/RP2D for the Combination of PLX2853 and Carboplatin | 0 | 0 |
Overall response rate as measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
No measurements were reported for this outcome.
Collected over Through 30 days after last dose of study drug, an average of 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PLX2853 Phase 2a Monotherapy | 5/14 (35.7%) | 6/14 (42.9%) | 14/14 (100%) |
| PLX2853 + Carboplatin Phase 1b/2a Combination Therapy | 11/23 (47.8%) | 10/23 (43.5%) | 20/23 (87%) |
| Event | PLX2853 Phase 2a Monotherapy | PLX2853 + Carboplatin Phase 1b/2a Combination Therapy |
|---|---|---|
| anemiaBlood and lymphatic system disorders | 2/14 | 1/23 |
| obstruction gastricGastrointestinal disorders | 2/14 | 1/23 |
| dehydrationMetabolism and nutrition disorders | 0/14 | 2/23 |
| sepsisInfections and infestations | 1/14 | 0/23 |
| abdominal painGastrointestinal disorders | 1/14 | 0/23 |
| thrombocytopeniaBlood and lymphatic system disorders | 1/14 | 0/23 |
| hepatic hematomaHepatobiliary disorders | 1/14 | 0/23 |
| fatigueGeneral disorders | 1/14 | 0/23 |
| large intenstinal obstructionGastrointestinal disorders | 1/14 | 0/23 |
| small intestinal obstructionGastrointestinal disorders | 1/14 | 1/23 |
| Event | PLX2853 Phase 2a Monotherapy | PLX2853 + Carboplatin Phase 1b/2a Combination Therapy |
|---|---|---|
| NauseaGastrointestinal disorders | 11/14 | 18/23 |
| Platelet count decreasedInvestigations | 4/14 | 16/23 |
| FatigueGeneral disorders | 7/14 | 13/23 |
| VomitingGastrointestinal disorders | 6/14 | 10/23 |
| AnemiaBlood and lymphatic system disorders | 6/14 | 6/23 |
| Abdominal painGastrointestinal disorders | 5/14 | 8/23 |
| ConstipationGastrointestinal disorders | 1/14 | 7/23 |
| Decreased appetiteMetabolism and nutrition disorders | 2/14 | 7/23 |
| DiarrheaGastrointestinal disorders | 4/14 | 7/23 |
| HyperglycemiaMetabolism and nutrition disorders | 4/14 | 4/23 |
| Age, Categorical(Participants) | PLX2853 Phase 2a Monotherapy | PLX2853 (40 mg) + Carboplatin Phase 1b | PLX2853 (80 mg) + Carboplatin Phase 1b | PLX2853 + Carboplatin Phase 2a Combination Therapy | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 2 | 4 | 9 | 25 |
| >=65 years | 4 | 1 | 3 | 4 | 12 |
| Sex: Female, Male(Participants) | PLX2853 Phase 2a Monotherapy | PLX2853 (40 mg) + Carboplatin Phase 1b | PLX2853 (80 mg) + Carboplatin Phase 1b | PLX2853 + Carboplatin Phase 2a Combination Therapy | Total |
|---|---|---|---|---|---|
| Female | 14 | 3 | 7 | 13 | 37 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | PLX2853 Phase 2a Monotherapy | PLX2853 (40 mg) + Carboplatin Phase 1b | PLX2853 (80 mg) + Carboplatin Phase 1b | PLX2853 + Carboplatin Phase 2a Combination Therapy | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 0 | 11 | 14 |
| Not Hispanic or Latino | 9 | 3 | 5 | 0 | 17 |
| Unknown or Not Reported | 2 | 0 | 2 | 2 | 6 |
| Race (NIH/OMB)(Participants) | PLX2853 Phase 2a Monotherapy | PLX2853 (40 mg) + Carboplatin Phase 1b | PLX2853 (80 mg) + Carboplatin Phase 1b | PLX2853 + Carboplatin Phase 2a Combination Therapy | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 | 0 | 4 |
| White | 11 | 1 | 4 | 11 | 27 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 0 | 0 | 0 | 3 |
| Region of Enrollment(participants) | PLX2853 Phase 2a Monotherapy | PLX2853 (40 mg) + Carboplatin Phase 1b | PLX2853 (80 mg) + Carboplatin Phase 1b | PLX2853 + Carboplatin Phase 2a Combination Therapy | Total |
|---|---|---|---|---|---|
| Canada | 0 | 0 | 0 | 3 | 3 |
| United States | 14 | 0 | 7 | 10 | 34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2020 to primary completion in Apr 2022, 20 months.
Results were first posted in Nov 2024, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zavabresib
Carcinoma, Ovarian Epithelial →
Opna Bio LLC